RxDoctor Payments DataLook up a doctor →

Nicole Nichols

Nurse Practitioner · Saint Louis, MONPI 1962836551

Payments from drug & device makers

$8,807in general payments, 2019–2025

Across 547 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$905
  • Pfizer$683
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$619
  • Sanofi$446
  • Takeda Pharmaceuticals U.S.A., Inc.$416
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$8,71599%
  • Education$921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,807 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$37,172
Medicare patients
199
Services billed
456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab14$195,405
Humira(Cf) PenAdalimumab18$136,579
ZenpepLipase/Protease/Amylase30$102,323
CreonLipase/Protease/Amylase14$69,102
Mesalamine86$44,724
LinzessLinaclotide33$29,261
MotegrityPrucalopride Succinate18$16,667
TrulancePlecanatide21$12,885
Mesalamine ErMesalamine31$12,763
DexilantDexlansoprazole12$10,128
AmitizaLubiprostone13$9,088
Dexlansoprazole DrDexlansoprazole29$8,402
Balsalazide Disodium61$7,462
Colestipol Hcl89$6,751
Lubiprostone18$5,844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$173$102,32330 claims
AbbVieCreon, Linzess$3,118$98,36347 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant, Amitiza$416$35,88443 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$619$12,88521 claims
SandozLansoprazole$13$1,66370 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →